Skip to main content
. 2016 Mar 4;9:1151–1158. doi: 10.2147/OTT.S96990

Table 1.

Characteristics of the eligible case–control studies enrolled in the meta-analysis

First author Year Ethnicity Genotyping method Control source Cancer type Case
Control
Y or N (HWE)
MM LM LL MM LM LL
Antognelli et al8 2005 Caucasian PCR-RFLP H-B Prostate cancer 67 197 120 43 169 148 Y
Van Der Logt et al18 2005 Caucasian PCR-RFLP P-B Colorectal cancer 59 166 139 50 162 140 Y
Stevens et al32 2006 Caucasian PCR-RFLP P-B Breast cancer 77 230 176 58 223 202 Y
Stevens et al19 2008 Mixed TaqMan P-B Prostate cancer 165 609 481 189 575 498 Y
Lurie et al17 2008 Mixed TaqMan P-B Ovarian cancer 192 65 14 276 145 24 Y
Arpaci et al11 2009 Caucasian PCR-RFLP H-B Ovarian cancer 5 19 27 2 27 25 Y
Antognelli et al16 2009 Caucasian PCR-RFLP P-B Breast cancer 325 115 107 231 125 188 N
Martinez et al31 2010 Caucasian TaqMan H-B Brain tumor 30 32 11 88 94 38 Y
Naidu et al23 2010 Asian PCR-RFLP P-B Breast cancer 50 178 159 17 109 126 Y
Uyar et al10 2011 Caucasian PCR-RFLP P-B Renal cell carcinoma 6 25 29 10 29 21 Y
Ergen et al28 2011 Caucasian PCR-RFLP P-B Osteosarcoma 3 23 24 9 20 21 Y
Aksoy-Sagirli et al26 2011 Caucasian PCR-RFLP H-B Lung cancer 10 94 119 14 102 118 Y
Hussein et al9 2011 Caucasian PCR-RFLP P-B Breast cancer 60 21 19 6 23 35 Y
Vecka et al27 2012 Caucasian PCR-RFLP H-B Pancreatic cancer 10 39 24 8 37 28 Y
Kokouva et al30 2013 Caucasian PCR-RFLP H-B Lymphohematopoietic cancers 60 139 117 50 159 142 Y
de Aguiar Goncalves et al25 2012 Mixed TaqMan H-B Acute leukemia 34 99 104 19 75 131 Y
Wang et al20 2012 Asian PCR-RFLP P-B Lung cancer 2 47 307 0 18 166 Y
Akkiz et al22 2013 Caucasian PCR-RFLP P-B Hepatocellular carcinoma 31 81 105 27 89 101 Y
Antognelli et al24 2013 Caucasian PCR-RFLP H-B Prostate cancer 100 291 180 131 540 497 Y
Vasconcelos et al29 2014 Mixed TaqMan P-B Embryonal tumor 15 56 85 25 134 177 Y
Ahmed et al21 2015 Asian PCR-RFLP P-B Colorectal cancer 2 10 38 16 24 40 N

Abbreviations: PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy–Weinberg equilibrium; Y, polymorphisms conformed to HWE in the control group; N, polymorphisms did not conform to HWE in the control group; H-B, hospital based; P-B, population based; L allele, leucine; M allele, methionine.